CTOR
Citius Oncology Inc
$
0.847
- Overview
- Forecast
- Valuation
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.897
Open
0.897
VWAP
0.85
Vol
33.19K
Mkt Cap
60.60M
Low
0.820
Amount
28.11K
EV/EBITDA(TTM)
--
Total Shares
71.55M
EV
65.96M
EV/OCF(TTM)
--
P/S(TTM)
--
Citius Oncology, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on oncology products. Its LYMPHIR (denileukin diftitox-cxdl) is approved by United States Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (a rare form of non-Hodgkin lymphoma) after at least one prior systemic therapy. LYMPHIR is a specially engineered IL-2- diphtheria toxin fusion protein made using recombinant DNA technology. It works by targeting cells that have IL-2 receptors with a toxin derived from diphtheria bacteria. It directly kills tumor cells by binding to the IL-2 receptors and internalizing the diphtheria toxin directly into the tumor cells, causing them to die. It boosts the body's immune response by reducing the number of regulatory T-cells (Tregs) that suppress the immune system, thereby enhancing the body's ability to fight the tumor.
Show More
Valuation Metrics
The current forward P/E ratio for Citius Oncology Inc (CTOR.O) is -4.63, compared to its 5-year average forward P/E of -1.29. For a more detailed relative valuation and DCF analysis to assess Citius Oncology Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.29
Current PE
-4.63
Overvalued PE
0.84
Undervalued PE
-3.42
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.73
Current PS
1.39
Overvalued PS
2.17
Undervalued PS
-0.72
Financials
Annual
Quarterly
FY2025Q1
0.00
Total Revenue
FY2025Q1
YoY :
+2282.37%
-6.39M
Operating Profit
FY2025Q1
YoY :
-1459.50%
-6.66M
Net Income after Tax
FY2025Q1
YoY :
-228.57%
-0.09
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CTOR News & Events
Events Timeline
2025-02-06 (ET)
2025-02-06
07:59:06
Citius Pharmaceuticals and Citius Oncology announce J-Code issued for Lymphir
2025-01-07 (ET)
2025-01-07
07:13:06
Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25
2025-01-06 (ET)
2025-01-06
06:52:15
Citius Oncology to explore strategic alternatives
Sign Up For More Events
Sign Up For More Events
News
1.0
05-05PRnewswireCitius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
2.0
04-01TipRanks3 Penny Stocks to Watch Now, 4/1/25
2.0
03-31BenzingaWhy Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Sign Up For More News
People Also Watch
NATH
Nathan's Famous Inc
98.820
USD
+0.08%
LPA
Logistic Properties of The Americas
6.120
USD
-7.13%
GOCO
Gohealth Inc
8.490
USD
+18.25%
AUDC
AudioCodes Ltd
8.420
USD
+3.31%
CANG
Cango Inc
4.080
USD
+2.26%
BLDE
Blade Air Mobility Inc
2.770
USD
+0.36%
MTW
Manitowoc Company Inc
8.560
USD
+2.64%
MPX
Marine Products Corp
8.330
USD
+0.97%
MVIS
MicroVision Inc
1.130
USD
0.00%
SPOK
Spok Holdings Inc
16.480
USD
-0.18%
FAQ
What is Citius Oncology Inc (CTOR) stock price today?
The current price of CTOR is 0.847 USD — it has decreased -2.53 % in the last trading day.
What is Citius Oncology Inc (CTOR)'s business?
What is the price predicton of CTOR Stock?
What is Citius Oncology Inc (CTOR)'s revenue for the last quarter?
What is Citius Oncology Inc (CTOR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Citius Oncology Inc (CTOR)'s fundamentals?
How many employees does Citius Oncology Inc (CTOR). have?